Clinical Trial Update: Neoadjuvant Study of Recombinant Vaccinia Virus to Treat Metastatic Colorectal Carcinoma in Patients Undergoing Complete Resection of Liver Tumors [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial of Pexa-Vec (JX-594), a recombinant vaccinia virus, for metastatic colorectal cancer in patients undergoing complete resection of live…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Pexa-Vec (JX-594) (recombinant vaccinia virus)

Snippet

Sponsor: Jennerex Biotherapeutics | Conditions: Colorectal Carcinoma | Phase 2 | Status: TERMINATED